GOTHENBURG, Sweden, Sept. 21, 2017

This study was published in the British Medical Journal (BMJ Open Gastro) July 2017

ProBion Clinica study demonstrates probiotic intervention response by altering colon-cancer-associated microbiota to non-cancer microbiota.

ProBion Innovation Sweden AB (PISA), a research biotechnology start-up, announces the results of a clinical trial, registration number NCT03072641, conducted by the Sahlgrenska Academy at University of Gothenburg, in Gothenburg, Sweden, utilizing ProBion Clinica with PISA's proprietary matrix technology on patients with colon cancer. Findings strongly confirm that the colon-cancer-associated microbial signature was modified d

Read more »